Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC
October 16, 2026 – October 16, 2027
This activity is jointly provided by Global Education Group (Global) and GO2 for Lung Cancer.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The primary audience for this project is multidisciplinary healthcare professionals (HCPs) involved in the diagnosis, treatment, and longitudinal care of patients with advanced mNSCLC, including those with HER2 (ERBB2)-mutations. This includes medical oncologists, nurse practitioners, physician assistants, oncology pharmacists, molecular pathologists, oncology nurses and navigators, and other team members integral to diagnosis, biomarker testing, treatment selection, and toxicity management, especially those practicing in community, under-resourced, and rural settings, where disparities in access to biomarker testing and targeted therapies remain most pronounced.
This educational initiative aims to improve the quality and equity of care for patients with advanced non-small cell lung cancer (NSCLC) by addressing gaps in biomarker testing and treatment decision-making. In support of this goal, the course Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2)-Mutant NSCLC is designed to enhance learners’ knowledge of tumor histology, molecular drivers, and the clinical significance of HER2 mutations. The activity responds to evidence showing that only 50% of eligible patients receive guideline-concordant biomarker testing, with delays in results contributing to suboptimal treatment selection and poorer outcomes, particularly when empiric therapy is initiated prior to testing. Additionally, persistent disparities in testing and targeted therapy use, linked to factors such as race, insurance status, and smoking history, highlight the need for improved education. This course seeks to equip clinicians with the foundational understanding necessary to support timely, appropriate, and equitable biomarker-driven care.
After completing this activity, the participant should be better able to:
1. Identify histologic subtypes of NSCLC and their molecular features.
2. Summarize the role of HER2 (ERBB2)- alterations (gene mutation, amplification, and protein overexpression) in NSCLC development.
3. Discuss hyperactivation of mutant HER2 receptors through increased homo- or heterodimerization and autophosphorylation.
4. Discuss how HER2 signaling pathways like MAPK, PI3K/AKT, PKC, and STAT result in uncontrolled cell proliferation and the development of HER2 (ERBB2)-mutant NSCLC.
Courtney Granville PhD, MSPH
30-minute online activity
In support of improving patient care, this activity has been planned and implemented by Global Education Group and GO2 for Lung Cancer. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group designates this continuing education activity for 0.5 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Disclosures of Relevant Financial Relationships Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.
For information about the Joint Accreditation (ACCME, ANCC) of this activity, please contact Global at 303-395-1782 or [email protected].
